Media Coverage

The BrightEdge Fund 2021 Annual Review
November 01, 2022

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers

read more
Interius Named as Finalist for the Deal of the Year Award by Life Sciences Pennsylvania
November 01, 2022

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers

read more
BioCentury’s 2021 Class of Emerging Companies
February 14, 2022

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers

read more
Interius Design: Penn Spinout Gets Specific with In Vivo CAR Ts
June 03, 2021
read more
Interius Biotherapeutics Nabs $76M Series A
May 18, 2021
read more
Penn Cell and Gene Therapy Spinout Interius Biotherapeutics Raises $76 Million
May 18, 2021
read more